Abstract
Asthma is a chronic inflammatory airways disorder mainly characterized by heterogeneity. In the more severe forms, a discordance often exists between symptoms and inflammation. Difficulty in managing asthma derives partly from the multiple phenotypes existing and our inability to recognize them. The use of non-invasive, with main representative the fraction of exhaled nitric oxide, or semi-invasive techniques such as induced sputum are effective tools that can help us to guide asthma treatment. In the latest years, several serum biomarkers related to asthmatic inflammation have been used for the better recognition of asthma sub-phenotypes to achieve optimization of therapy and disease outcome. In patients with mild–moderate asthma, as well as patients with more severe asthma, the use of blood eosinophils revealed an acceptable accuracy for the prediction of airway eosinophilia indicating that in future studies may facilitate both individualized treatment and management of asthma. None of the above techniques have been incorporated in clinical practice although sputum eosinophils can be used in patients with severe asthma particularly in specialized centers with great experience. Of great interest are blood eosinophils since current data support their role either as tool for treatment selections or/and as a biomarker of airway eosinophilia.
Similar content being viewed by others
Abbreviations
- ACQ:
-
Asthma control questionnaire
- FeNO:
-
Fraction of exhaled nitric oxide
- ICS:
-
Inhaled corticosteroids
- LABA:
-
Long-acting beta two-agonists
- NOS:
-
Nitric oxide synthase
References
Agache IO (2013) From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol 13:249–256
Alving K, Weitzberg E et al (1993) Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 6:1368–1370
Bakakos P, Schleich F et al (2011) Induced sputum in asthma: from bench to bedside. Curr Med Chem 18:1415–1422
Bartoli ML, Bacci E et al (2004) Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation. Respir Med 98:184–193
Bateman ED, Boushey HA et al (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170:836–844
Bateman ED, Hurd SS et al (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143–178
Bel EH, Wenzel SE et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189–1197
Belda J, Leigh R et al (2000) Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 161(2 Pt 1):475–478
Bergeron C, Tulic MK et al (2007) Tools used to measure airway remodelling in research. Eur Respir J 29:596–604
Berry M, Morgan A et al (2007) Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 62:1043–1049
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
Boulet LP, FitzGerald JM et al (2015) The revised 2014 GINA strategy report: opportunities for change. Curr Opin Pulm Med 21:1–7
Chlumsky J, Striz I et al (2006) Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 34:129–139
Chung KF, Wenzel SE et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43:343–373
Corren J, Lemanske RF et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088–1098
de Jongste JC, Carraro S et al (2009) Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 179:93–97
Djukanovic R, Wilson SJ et al (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583–593
Dupont LJ, Demedts MG et al (2003) Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 123:751–756
Dweik RA, Boggs PB et al (2011) An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184:602–615
Gratziou C, Lignos M et al (1999) Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. Eur Respir J 14:897–901
Green RH, Brightling CE et al (2002a) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360:1715–1721
Green RH, Brightling CE et al (2002b) Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57:875–879
Guo FH, Comhair SA et al (2000) Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol 164:5970–5980
Haldar P, Pavord ID et al (2008) Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178:218–224
Haldar P, Brightling CE et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973–984
Hamid Q, Song Y et al (1997) Inflammation of small airways in asthma. J Allergy Clin Immunol 100:44–51
Hamid QA, Wenzel SE et al (1999) Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 159(5 Pt 1):1600–1604
Hanania NA, Alpan O et al (2011) Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154:573–582
Hanania NA, Wenzel S et al (2013) Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187:804–811
Hargreave FE, Nair P (2011) Point: is measuring sputum eosinophils useful in the management of severe asthma? Yes. Chest 139:1270–1273
Holgate S, Buhl R et al (2009) The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 103:1098–1113
Honkoop PJ, Loijmans RJ et al (2015) Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol 135(682–688):e11
Jayaram L, Parameswaran K et al (2000) Induced sputum cell counts: their usefulness in clinical practice. Eur Respir J 16:150–158
Jayaram L, Pizzichini MM et al (2006) Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27:483–494
Juniper EF, Bousquet J et al (2006) Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the asthma control questionnaire. Respir Med 100:616–621
Kallen B, Finnstrom O et al (2013) Association between preterm birth and intrauterine growth retardation and child asthma. Eur Respir J 41:671–676
Kharitonov SA, Barnes PJ (2001) Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 163:1693–1722
Kharitonov SA, Yates D et al (1994) Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343:133–135
Kostikas K, Papaioannou AI et al (2008) Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest 133:906–913
Kraft M (2011) Asthma phenotypes and interleukin-13—moving closer to personalized medicine. N Engl J Med 365:1141–1144
Louis R, Lau LC et al (2000) The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161:9–16
Loukides S, Kostikas K et al (2011) Non-invasive assessment of asthmatic inflammation: from bench to bedside. Curr Med Chem 18:1413–1414
Martin RJ, Szefler SJ et al (2007) The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol 119:73–80
Michils A, Baldassarre S et al (2008) Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 31:539–546
Michils A, Louis R et al (2009) Exhaled nitric oxide as a marker of asthma control in smoking patients. Eur Respir J 33:1295–1301
Murphy VE, Schatz M (2014) Asthma in pregnancy: a hit for two. Eur Respir Rev 23:64–68
Nair P, Pizzichini MM et al (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360:985–993
Ortega HG, Liu MC et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198–1207
Papaioannou AI, Minas M et al (2009) Exhaled NO may predict loss of asthma control: the effect of concomitant allergic rhinitis. Eur Respir J 34:1006–1007
Petsky HL, Cates CJ et al (2012) A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 67:199–208
Pijnenburg MW, Bakker EM et al (2005) Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 172:831–836
Pin I, Gibson PG et al (1992) Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 47:25–29
Powell H, Murphy VE et al (2011) Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 378:983–990
Quaedvlieg V, Sele J et al (2009) Association between asthma control and bronchial hyperresponsiveness and airways inflammation: a cross-sectional study in daily practice. Clin Exp Allergy 39:1822–1829
Reddel HK, Bateman ED et al (2015) A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 46:622–639
Schleich FN, Seidel L et al (2010) Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 65:1039–1044
Shaw DE, Berry MA et al (2007) The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 176:231–237
Simpson JL, Scott R et al (2006) Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 11:54–61
Smith AD, Cowan JO et al (2004) Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 169:473–478
Smith AD, Cowan JO et al (2005) Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352:2163–2173
Szefler SJ, Martin RJ et al (2002) Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109:410–418
Szefler SJ, Mitchell H et al (2008) Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 372:1065–1072
Tseliou E, Bessa V et al (2010) Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest 138:107–113
Wagener AH, de Nijs SB et al (2015) External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 70:115–120
Wenzel SE, Schwartz LB et al (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160:1001–1008
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors have any conflicts to disclose.
About this article
Cite this article
Tsilogianni, Z., Ntontsi, P., Papaioannou, A.I. et al. Biomarkers Guided Treatment Strategies in Adult Patients with Asthma: Ready for the Clinical Field?. Arch. Immunol. Ther. Exp. 65, 1–9 (2017). https://doi.org/10.1007/s00005-016-0407-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-016-0407-9